Key Drivers
- Margin Improvement
- Strong Liquidity
- Ongoing Cash Burn
AIAI Summary
Iovance's investable shift is that Amtagvi's ~$100M quarterly revenue and 56% gross margin indicate a potentially scalable TIL commercial model, but after a sharp rerating investors should require sustained utilization-driven growth, lower cash burn, and strong lung-cancer data before adding exposure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Improvement
- •Strong Liquidity
- •Ongoing Cash Burn
IOVA shows improving revenue, margins, liquidity, and leverage, but persistent losses, cash burn, dilution, and a high sales multiple make it a high-risk investment.
Price Behavior
Key Price Behavior Insights:
- •Strong uptrend
- •Accelerating momentum
- •Pullback risk
IOVA gained 24% over the last month to $10.25, but its RSI near 81 signals elevated pullback risk unless it decisively breaks above resistance.
Rapid rise from $8.14 to $10.25 after 2026-09-10
Sentiment & News
Key News Insights:
- •Amtagvi sales growth
- •NSCLC data catalyst
- •Mixed institutional activity
Iovance's surge reflects strong Amtagvi sales momentum and upcoming lung-cancer data catalysts, though mixed institutional trading signals warrant caution.
Positive operating momentum and clinical catalysts could sustain investor interest, but volatility may remain elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings